Novo Nordisk President and CEO Talks Wegovy Pill

Summary

Bloomberg Talks: Novo Nordisk President and CEO Talks Wegovy Pill

Date: December 23, 2025
Host: Katie Greifeld (Bloomberg)
Guest: Mike Dostar, President and CEO of Novo Nordisk

---

Episode Overview

This episode features a timely and revealing interview with Mike Dostar, President and CEO of Novo Nordisk, following the FDA approval of the oral (pill) version of their blockbuster obesity drug Wegovy. The discussion centers on the significance of this breakthrough, Novo Nordisk’s competitive strategy, supply and distribution plans, market expansion, pricing, and future ambitions. Dostar shares insights on how this first-to-market pill could reshape obesity treatment, address patient hesitancy, and expand opportunities for both the company and patients worldwide.

---

Key Discussion Points & Insights

1. First-to-Market Advantage and Product Efficacy

(00:34 - 01:21)

• Dostar expresses excitement about being first to launch an oral GLP-1 for obesity in the United States, ahead of Eli Lilly.
• He emphasizes:
  • The Wegovy pill delivers up to 17% efficacy in weight loss if taken regularly.
  • 1 in 3 users may experience up to 20% weight loss.
• Dostar underscores the importance:
  "Christmas comes early... this is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP1 pill." (01:21 – Mike Dostar)

2. Competing with Eli Lilly and Drug Functionality

(02:03 – 02:22)

• Katie highlights competitors, especially Eli Lilly, whose pill is set to launch two months later and may offer fewer restrictions.
• Dostar responds:
  • Emphasizes comparable efficacy between the injection and pill form.
  • Stresses >10 years of safety data backing their GLP-1.
  • Glows about the dual benefits: “Not only going to reduce your weight, it also has protection for your cardiovascular systems. So this is a phenomenal pill, second to none, I would say.” (02:22 – Mike Dostar)

3. Distribution and Sales Channels

(03:17 – 03:57)

• Dostar confirms a broad launch strategy:
  • Will sell via NovoCare Pharmacy, RO, LifeMD, Costco, Weight Watchers, TrumpRx (coming soon), and traditional pharmacies.
• Key quote:
  "Everyone that you can imagine is going to start launching this at the same time on the day of the launch." (03:27 – Mike Dostar)

4. Scaling up Supply and Overcoming Challenges

(03:57 – 05:25)

• Dostar recounts the scientific breakthrough in putting peptides in a pill, describing it as previously "impossible."
• Confident in manufacturing capacity:
  “We have shown confidence that we are able to scale this more than enough for every single person who would want to take the pill. And we are ready for that.” (04:14 – Mike Dostar)
• Asserts affordability and scalability, calling the product:
  "Borderline miracle in my own humble opinion, a peptide in a pill with a high efficacy produced at scale and we're going to actually sell it through all channels at relatively affordable price." (05:12 – Mike Dostar)

5. Market Expansion vs. Cannibalization Concerns

(05:25 – 06:29)

• Katie asks whether the pill could expand the total market or merely cannibalize injectables.
• Dostar predicts significant market growth, citing people hesitant about injections:
  "There are a number of people... they have not... taken that journey because they've been either afraid of injections or there is a taboo of injection. I think a lot of these people today will be able to find wegovy pill incredibly interesting as a way to come in." (05:42 – Mike Dostar)
• Emphasizes new patient access because of the pill format.

6. Pricing and Political Context

(06:29 – 07:23)

• Reference to pricing deals with the Trump administration.
• Dostar stresses commitment to affordability and access:
  • Starting price of $149 for oral Wegovy—asserted as accessible to many.
  • Pledges to monitor and adjust prices to maintain broad access as the market expands.
• Quote:
  "We have announced that we will start the starting dose of the begovi pill at 149, which I think is a very affordable price for many Americans to, to get interested at." (06:46 – Mike Dostar)

7. Mergers & Acquisitions and Future Strategy

(07:23 – 08:24)

• Katie probes on future acquisitions after losing a bidding war with Pfizer over Med Sarah.
• Dostar affirms active efforts to seek pipeline enhancements:
  • “We have made it very clear that we would like to sustain our leadership in diabetes and obesity and go very deep. We have a fantastic pipeline in both of those therapy areas, but the world is very large. We are dealing with some close to 2 billion people... you will continue looking not just in your own research shop but everywhere else…” (07:40 – Mike Dostar)
• Novo Nordisk’s intent: stay competitive through internal R&D and external deals.

---

Notable Quotes and Memorable Moments

• "Christmas comes early... this is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP1 pill."
  — Mike Dostar, (01:21)

• "For the first time ever, people do not to have compromise between either taking an efficacious injection or a convenient pill... you have the same efficacy of 17% in injection or appeal."
  — Mike Dostar, (02:22)

• "Everyone that you can imagine is going to start launching this at the same time on the day of the launch."
  — Mike Dostar, (03:27)

• "Borderline miracle in my own humble opinion, a peptide in a pill with a high efficacy produced at scale and we're going to actually sell it through all channels at relatively affordable price."
  — Mike Dostar, (05:12)

• "I think the market will expand quite a bit actually for many of these people that have just been waiting and seeing the injectable versions of these GLP1 products. Taking, taking the world by storm."
  — Mike Dostar, (06:03)

• "We have announced that we will start the starting dose of the begovi pill at 149, which I think is a very affordable price for many Americans to, to get interested at."
  — Mike Dostar, (06:46)

• "...you will continue looking not just in your own research shop but everywhere else to see how complementary wise you could actually have the best pipeline available and the best offering amongst all your competitors."
  — Mike Dostar, (07:58)

---

Timestamps for Important Segments

• Novo Nordisk’s first-to-market advantage and product benefits: 00:34–02:03
• Discussion of competition, efficacy, and safety: 02:03–03:17
• Distribution plans and launch channels: 03:17–03:57
• Scaling production and technical breakthroughs: 03:57–05:25
• Market expansion and consumer hesitancy: 05:25–06:29
• Pricing and political factors: 06:29–07:23
• M&A and future innovation strategy: 07:23–08:24

---

Conclusion

The interview offers a revealing look into Novo Nordisk’s ambition with the Wegovy pill—bridging science, accessibility, and business strategy. Dostar’s conviction in the product’s efficacy, availability, and transformative market potential is unmistakable. The conversation explores not only commercial and technical aspects but also broader issues like access, affordability, and the ongoing role of innovation and acquisitions in healthcare. For listeners, it’s a comprehensive preview of how the oral GLP-1 category could redefine obesity treatment and competition in 2026.

Transcript

[Indiana University Narrator]

Old playbooks won't solve tomorrow's problems. Indiana University is proving how higher education can create solutions with industry. Our partnerships address future talent and workforce needs, support entrepreneurs and local businesses, and create solutions that turn discoveries into dollars. Together, we're building a model for industry partnerships that fuel economic growth. Explore IU's impact at iu.edu impact.

[CVS Pharmacy Narrator]

Bloomberg Audio Studios Podcasts Radio news Now for.

[Katie Greifeld]

Our top corporate story of the morning. Novo Nordisk shares rising in premarket trading. This after the drugmaker wins approval to sell a pill version of its blockbuster obesity drug Wegovy. Joining us now with a special guest, Katie Greifeld. Hey, Katie. Hey, Anne Marie. Thank you very much. Joining me now, I'm pleased to say, is the CVO of Novo Nordisk. His name is Mike Dostar. Mike, great to have you with us. Just to set the seen here, when it comes to the US market, you've been losing share to your rival Eli Lilly for a couple of years now. But with this approval, you have an important first mover advantage when it comes to oral GLP ones. Given that you expect to start selling the pill version of Wegovy in January, whereas Eli Lilly isn't due on the market until March, how do you plan to make the most of this head start?

[Mike Dostar]

Thanks very much for having me, Katie. As they say, Christmas comes early. So I'm super excited, of course, to be here announcing the, you know, the Begovia pill. As you say, this is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP1 pill. And for the first time, we are having a pill that has an efficacy of some 17% if you take the pill regularly. And one in three people are going to actually reduce up to 20% weight loss. I think that data speaks for itself and we are super excited, of course, to be the first to the market and, and we're going to go all in trying to make this a huge success.

[Katie Greifeld]

Well, moving forward, I mean, beyond just these first few months after Eli Lilly does have their pill on the market, how do you plan to compete? What is your strategy there, given? My understanding is that there's likely going to be no restrictions when it comes to food, when it comes to drinks around Lilly's version.

[Mike Dostar]

Yeah. So as I mentioned, there are no other phase three trials of oral GLP1 that has shown this level of efficacy. This means that for the first time ever, people do not to have compromise between either taking an efficacious injection or a convenient pill for the first time ever you have the same efficacy of 17% in injection or appeal. You can take it on a daily basis as a pill or a weekly injection. And that, I think is the key selling point with Wegovy Pill. We also have more than 10 years, years of, of course, experience with regards to safety data and what have you. That's why it's called the Wegovy pill, which means that this pill is not only going to reduce your weight, it also has protection for your cardiovascular systems. So this is a phenomenal pill, second to none, I would say, and we are very ready to compete with it.

[Katie Greifeld]

Let's talk about how you're going to sell it. Through what channels will you sell this way? Govy pill. And will all of those channels be available at launch?

[Mike Dostar]

The quick answer is yes, we're going all in. We're of course going to sell this through our own websites, Novocare Pharmacy, as well as all of our partners, RO Life md, Costco, Weight Watchers. Everyone that you can imagine is going to start launching this at the same time on the day of the launch. Trump rx, of course, will be coming up soon as well, as well as, of course, the traditional channels that usually medicine is procured in us.

[Katie Greifeld]

Well, to that point that you know it's going to be widely available. Let's talk about supply. I know that you've already started production. How confident are you that you're going to be able to meet all of that demand at launch, given, of course, the supply challenges that you've been through in the past?

[Mike Dostar]

Let me take you back. You know, 10 years ago, when we started the journey of putting a peptide into a pill, no one thought scientifically that is possible. You have to remind your audience that pills are usually chemical entities, small molecules and not proteins and peptides, and, and often they have lower efficacy because of that. When, when we decided to actually go this route, everyone thought, scientifically this is impossible. Then after that, when we proved them wrong, people thought that we cannot scale that because this is quite difficult to do. Again, because it's large molecule inside a pill. Again, we have shown confidence that we are able to scale this more than enough for every single person who would want to take the pill. And we are ready for that. Of course, lastly, people are writing us off that, you know, this would not be possible at an affordable price. And I'm also very happy to say, once again, we are proving all of these skeptics wrong. So I'm super excited that we have something that is borderline miracle in my own humble opinion, a peptide in a pill with a high efficacy produce at scale and we're going to actually sell it through all channels at relatively affordable price.

[Katie Greifeld]

I'm curious how you see this market evolving, whether you think that, you know, having this pill version available will span the total addressable market, the total number of patients that you can reach, or whether or not it might cannibalize the injectables that you're already serving.

[Mike Dostar]

You know, in my own family and circle of friends, there are a number of people that have been very attracted in taking a GLP1 product and reducing weight. Unfortunately, they have not, you know, taken that journey because they've been either afraid of injections or there is a taboo of injection. I think a lot of these people today will be able to find wegovy pill incredibly interesting as a way to come in get the same efficacy as your injection, but in a form factor of appeal. So in short, I think the market will expand quite a bit actually for many of these people that have just been waiting and seeing the injectable versions of these GLP1 products. Taking, taking the world by storm.

[Katie Greifeld]

And of course we have to talk about pricing and how that plays into the political picture. Many drug makers, yourself included, have made pricing deal deals with the Trump administration. And given that those deals have already been made, what additional political hurdles do you see, if any in 2026?

[Mike Dostar]

Well, again, the whole, the whole negotiation with Trump's administration has been around providing access at an affordable price. And we have announced that we will start the starting dose of the begovi pill at 149, which I think is a very affordable price for many Americans to, to get interested at. And, and I will say that as we go forward, of course we will very much like to continue expanding the market and we will make sure that the price levels are in a way that, that, that, that, that, that will make us do that.

[Katie Greifeld]

And Mike, before I let you go, I have to ask you about M and A. Of course you had that high profile bidding war with Pfizer over Med. Sarah Pfizer ultimately came out on top. But with that in the background, are you still, still looking to pursue deals here, deals here to help fill out your pipeline, so to speak?

[Mike Dostar]

Absolutely. We have made it very clear that we would like to sustain our leadership in diabetes and obesity and go very deep. We have a fantastic pipeline in both of those therapy areas, but the world is very large. We are dealing with some close to 2 billion people that are suffering from diabetes, obesity and overweight. And when you are having an ambition to actually capture aspects many patients as possible from this very large pool then then you will continue looking not just in your own research shop but everywhere else to see how complementary wise you could actually have the best pipeline available and the best offering amongst all your competitors.

[Katie Greifeld]

Well Mike, I know it is a big day for Novo Nordisk. I really appreciate you taking the time for Bloomberg Television. Happy holidays when you get there. That is Mike Dostar. He is the CEO of of Novo Nordisk.

[Indiana University Narrator]

Old Playbooks Won't solve Tomorrow's problems Indiana University is redefining the relationship between higher education and industry. We're addressing future talent and workforce needs through more than 10,000 industry partnerships, supporting and investing in young entrepreneurs and businesses that create jobs and grow the economy, and facilitating the research and development that lead to breakthrough solutions. This isn't business as usual. Indiana University Industry is a partnership that fuels economic growth. Explore IU's impact at IU.edu impact@CVS it.

[CVS Pharmacy Narrator]

Matters that we're not just in your community, but that we're part of it. It matters that we're here for you when you need us, day or night. And we want everyone to feel welcomed and rewarded. It matters that CVS is here to fill your prescriptions and here to fill your craving for a tasty and, yeah, healthy snack. At cvs, we're proud to serve your community because we believe where you get your medicine matters. So visit us at cvs. Com or just come by our store. We can't wait to meet you. Store hours vary by location.